Breaking news on the opening page of a document as traditionally retrospective as an annual report may seem a tad unorthodox. However, shortly before this publication reached the presses, I was able to conclude a process whose outcome is so fundamental to the continued success of Whitehead Institute that I can think of no medium more appropriate for its announcement.
As supporters and friends of the Institute well know, my top priority as Director has been faculty recruitment. Last year in this space, I described a Board-approved plan for new faculty hires. Now, after an exhaustive search and thorough vetting of a remarkably deep pool of candidates, I'm delighted to inform you that two exceptionally creative young scientists will soon join our ranks. You'll learn much more about these talented individuals in the months and years to come, but allow me to introduce them briefly. College. Mary's arrival heralds a welcome return to our roots in plant biology. She'll fill our seventh-floor greenhouse with Arabidopsis thaliana, which she'll use as a model in which to study epigenetic reprogramming. Her work will provide valuable insights into this and other developmental processes not only in plants but in mammals as well, and will complement research occurring in several other Whitehead labs.
Mary's cross-country journey to Cambridge is considerably longer than that taken by cancer researcher Piyush Gupta.
An honors graduate of the University of Chicago, Piyush earned his PhD under the tutelage of our own Bob Weinberg and became a postdoctoral research associate with our neighbor and former Whitehead Member Eric Lander at Broad Institute. Piyush is studying the genes and signaling networks that control both normal epithelial stem cells and cancer stem cells. His research will add to Whitehead's already considerable contributions in this arena.
In addition to these faculty hires, our Whitehead Fellows program, which allows a handful of particularly promising, newly minted scientists to establish labs and pursue their own research agendas over a four-or five-year period, has attracted a new recruit. Yaniv Erlich, who graduated from Tel-Aviv University with honors degrees in biology and psychology, recently completed his doctorate at Watson
School of Biological Sciences at Cold Spring Harbor
Laboratory. Yaniv will focus on high-throughput personal genomics during his time here.
The excitement generated by the launching of these three careers aligns perfectly with a theme of this report: "What I thought then…What I know now." Within these pages, our Members recount conceptual shifts and occasional surprises that can alter a continuum of research. We can't predict what those might be for Mary, Piyush, and Yaniv, but it's thrilling to know they're about to find out for themselves.
In closing, I should note that all three newcomers had multiple suitors vying for their services. That they have chosen Whitehead Institute is a tribute to our faculty, staff, friends, and supporters, whose passion and dedication make ours such a uniquely appealing culture. And for that, I am extraordinarily grateful. In the Xenopus frog embryo, opening the primary mouth (bracketed in the image at left) depends on the dissolution of the basement membrane (stained green). If the Wnt signaling pathway is interrupted, the basement membrane remains intact (right image).
sTeM cells

When the program needs editing
The discovery of cellular reprogramming brought with it enough hope to obscure the fact that, though extraordinary, the process was far from perfect. The successful reversion of fully matured cells to an embryonic stem cell-like statefrom which they could have the potential to become any cell type in the body-was practically the stuff of science fiction. But the earliest reprogramming efforts relied on the use of viruses to deliver four genes into the DNA of adult cells. The approach is problematic, in part because one of the inserted genes (c-Myc) is known to cause cancer, and in part because all of the genes introduced may interact with as many 3,000 existing genes, resulting in unintended and undesired changes in overall gene expression. In 2009, researchers in the lab of Member Rudolf Jaenisch advanced the field with a ground-breaking, two-part experiment with both methodological and clinical implications.
In the first portion of the experiment, scientists reprogrammed skin cells from Parkinson's disease (PD) patients to an induced pluripotent state. They achieved this by inserting the four known reprogramming genes along with another gene coding for the enzyme Cre. The scientists also bracketed the reprogramming genes with short DNA sequences called loxP, which respond to the Cre enzyme.
Post-insertion, the team introduced Cre into the cells, triggering a reaction at the loxP sites that caused a deletion of all four of the target genes. Beyond successful removal of the genes, expression analysis of these induced pluripotent stem cells revealed their genomes to be virtually identical to those of the PD patients from whom the original skin cells came. Notes Jaenisch: "Other labs have reprogrammed mouse cells and removed the reprogramming genes, but it was incredibly inefficient, and they couldn't get it to work in human cells. We have done it much more efficiently, in human cells, and made reprogrammed, gene-free cells."
In the second part of the experiment, the researchers used the new pluripotent cells to derive patient-specific, dopamine-producing neurons. Destruction of these cells is a hallmark of PD, but the study of their degeneration is hampered because of their inaccessible location in the brain. The creation of these cells from individual patients is a critical step in attaining what's known as the diseasein-a-dish paradigm; that is, the establishment of patientderived models to enhance our understanding of heretofore inscrutable disease processes.
Parkinson's disease (PD) causes neurodegeneration, leading to insufficient levels of the neurotransmitter dopamine. Via cellular reprogramming, the Jaenisch lab derived from the skin cells of PD patients neurons capable of producing dopamine (stained green in the image above) and an enzyme found only in dopaminergic neurons (stained red).
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Targeting tumor growth
In the therapeutic battle against malignant tumors, cancer stem cells (CSCs) are formidable adversaries. Although few in number, these cells have the ability to seed new tumorsnot only at the primary site but also at remote sites in the body. Moreover, they are resistant to standard chemotherapies. Their existence explains why many solid tumors shrink dramatically after treatment, only to reform later. Attempting to find drugs that target CSCs has been an appealing proposition, but such efforts have been hampered by the cells' scarcity. There simply aren't enough of them in tumor samples to allow for large-scale compound screenings.
However, a discovery in the lab of Member Robert Weinberg is changing that. By inducing in certain tumor cells a change known as an EMT (or epithelial-mesenchymal transition), scientists in the Weinberg lab are able to produce large, stable populations of CSCs. Weinberg lab members and collaborators recently employed this technique to enable a screen of roughly 16,000 compounds for anti-CSC activity in breast cancer tumors. During the screen, scientists found that a drug called salinomycin was 100-times more effective than the anti-cancer agent paclitaxel at reducing the number of CSCs in breast tumors. It's too early to know whether salinomycin could be used to treat cancer in humans, but the research that unearthed its potential suggests a fundamental approach for finding novel drugs.
Underlying the development of many cancerous tumors is abnormal cell growth. Such aberrant growth is often caused by a mutation in or deletion of tumor suppressor genes, which, as the name implies, serve to constrain improper cell division. An estimated 70 percent of men with prostate cancer, for example, have a deletion of the known tumor suppressor gene PTEN. In mouse models of human prostate cancer, as one might expect, tumors form in the absence of PTEN. However, researchers in the lab of Member David Sabatini recently discovered that tumor growth also requires the presence of a protein complex known as mTORC2, part of a pathway that plays a critical role in regulating cell growth. As it turns out, mTORC2 is so integral to tumor formation, that inhibiting its activity halts the development of tumors-even in cells lacking PTEN.
Interestingly, mTORC2 inhibition in normal cells appears to have little or no impact, which may make mTORC2 a potential therapeutic target.
Mice lacking the tumor suppressor gene PTEN develop prostate tumors (see arrow, above center). Inhibiting the mTORC2 protein complex in these mice prevents tumor formation (above right), lending prostate tissue an appearance similar to that of mice with functional PTEN (above left).
inFecTiOUs Disease
Resistance may be futile Drug-resistant fungal infections in immunocompromised patients can have deadly consequences. Such infections in these patients-including those undergoing chemotherapy, receiving organ transplants, or battling HIV-are associated with mortality rates ranging from 50 to 90 percent. At issue are fungi's ability to evolve resistance to antifungal drugs in rapid fashion, thanks in part to the activity of a heat-shock protein known as Hsp90. Hsp90 appears to trigger a stress response in fungi, prompting adaptations rendering the fungi impervious to therapeutic intervention. Impeding Hsp90, researchers in the lab of Member Susan Lindquist surmised, might offer an approach to overcoming drug resistance. Blocking Hsp90 on its own proved ineffective, but combining Hsp90 inhibitors with common antifungal drugs delivered a deadly blow to the fungi Candida albicans and Aspergillus fumigatus, two of the most prevalent sources of human fungal infections. "This is an entirely new strategy for making fungi susceptible to preexisting drugs and for preventing fungi from deploying the resistance mechanisms they have evolved against those compounds," Lindquist says. "It could make the difference between life and death." Thus far, the work has exposed a gene used by diphtheria toxin and an enzyme influenza virus hijacks during cellular invasion. Says Brummelkamp: "In addition to many aspects of cell biology that can be studied, knockout screens could also be used to unravel molecular networks that are exploited by a battery of different viruses and bacteria."
A human cell line with a single copy of each gene, except the genes on chromosome 8 (shown above), forms the basis of a new genetic screen. By "knocking out" individual genes in this cell line, Whitehead scientists can now identify genes that are hijacked by invading pathogens. 
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The discovery was a blow to the group of scientists convinced that the human Y chromosome is moving inexorably toward extinction. Those heralding the Y's demise noted that the chromosome had steadily been losing genes throughout evolution.
Further, these fatalists argued, without a partner with which to swap genes to maintain genetic quality and diversity, the Y would continue to shed genes until its decay was complete. But from the Whitehead lab of Member (now Director) David Page came a defiant "Not so fast!" (or the academic equivalent thereof).
Some six years ago, with the help of collaborators at Washington University in St. Louis, Page completed the sequencing of the Y and, along the way, discovered eight large regions of mirror-imaged genetic sequences, or palindromes. It turns out that in the absence of another chromosome with which to pair and exchange genes, the Y, by folding at its palindromic regions, actually trades genes with itself. It's an elegant mechanism that has ensured the Y's evolutionary survival. Now, however, it appears the Y's process of self-preservation may also be responsible for a range of sex disorders, from failed sperm production to sex reversal to Turner syndrome. The Page lab recently found that the process may randomly go awry, turning the entire chromosome into a palindrome. The result is a so-called isodicentric Y chromosome (idicY)-an abnormal structure with two centromeres. In a comprehensive review of DNA samples from nearly 2,400 sex disorders patients who had been studied over many years, idicYs were found in 51 patients. Page et al determined that these idicYs were associated with spermatogenic failure in a number of male patients. But then they discovered something else: 18 of those 51 patients were anatomically female, despite carrying two copies of the sex-determining SRY gene on their idicY chromosomes. Suspecting that this feminization was related to instability inherent to idicYs, and subsequently finding that the instability increases with the size of the chromosome, Page arrived at the seemingly paradoxical conclusion that the larger the Y chromosome, the greater the likelihood of sex reversal.
This new model for the formation of idicY chromosomes, along with the size-instability correlation, may explain a possible cause of Turner syndrome, an abnormality in girls or women characterized by the lack of one sex chromosome. Page now believes a sizeable percentage of the disorder could be caused by this palindrome-to-palindrome recombination.
explaining The 'Y' behind sex disorders
Formation of an isodicentric Y chromosome is depicted in the drawing below left. Crossing over between arms at a palindrome (denoted by the X in the graphic) results in an isodicentric Y chromosome (right of the arrow) with two centromeres (blue dots) and two copies of the masculinizing SRY gene. The image below right depicts four isodicentric Y chromosomes. The Page lab discovered that instability of the chromosome increases with the distance between the centromeres-and, that the more unstable the chromosome, the more likely the loss of genetic material during mitosis. Such loss increases the likelihood of sex reversal. 
IntensIty
YeasT Rising
After centuries of study, the utility of this humble organism continues to expand
after centuries of study, the utility of this humble organism continues to expand. Today many human vaccines and therapeutic proteins such as insulin are produced in yeast using these technologies.
While Fink was studying genetics and physiology in yeast, other researchers were using it to study cancer.
"Do these cells get cancer? The answer is no," says Fink. "But once you find a pathway that is important for cancer, you can use yeast to study it."
Lindquist later took the notion of studying human diseases in yeast in an entirely different direction when she began working on models for the neurological disorders Huntington's disease (HD) and Parkinson's disease (PD). Leveraging techniques from
Fink's work, Lindquist was able to genetically modify yeast cells to overproduce key proteins linked to both diseases: huntingtin in HD and alpha-synuclein in PD. This approach enables the Lindquist lab to study the effects of these potentially harmful proteins and to devise ways to disrupt their overproduction and aggregation.
More recently, Lindquist used yeast to create a platform with which to conduct rapid, cost-effective screens for potential PD
drugs. This year, her lab identified four compounds capable of restoring normal cellular functions in yeast PD models. Significantly, these compounds also rescue neurons in rat models of PD. Lindquist also employed yeast to uncover the first definitive causal link between genetics and the environment in PD, finding that the gene PARK9 protects cells from alpha-synuclein overexpression and exposure to manganese toxicity. Used for thousands of years in baking bread and brewing beer, the yeast Saccharomyces cerevisiae, shown in colony form at left, has been a focus of biological study since the late 19 th Century. In Whitehead Institute laboratories, S. cerevisiae and other yeasts are integral to genetic, human disease, and cell biology research. 
Iain Cheeseman
Principal Investigators
Whitehead Faculty comprises 14 scientists, each among the world's best in his or her chosen field. Collectively, it is a formidable group of unparalleled caliber whose work has had an indelible impact on the landscape of biomedical research. In other work, the Bartel lab has identified a link between truncated forms of mRNAs and cancer. Structurally, mRNAs consist of three sections. The first section initiates protein production, the middle section codes for the actual protein, and the tail section is where miRNAs and other types of regulatory molecules usually interact with the mRNA to help determine how much protein is made. The Bartel lab found that for many mRNAs the tail section tends to be shorter in cancer cells and that when the tail section is shortened, the mRNA produces about ten times more protein than when the tail section is longer. Moreover, they found that trimming the tail ends of certain mRNAs in healthy cells can convert them into cancer-like cells. One of the goals now is to decipher how cancer cells shorten their own mRNAs en route to protein overproduction.
What I thought then… "According to the classic view that started in 1993 and persisted for over a decade, microRNAs act as on/off switches to repress a few key messenger RNA targets, thereby initiating a developmental transition."
What I know now… " …Pretty much all of the elements of the classical view have been revised since we and others have learned more about microRNAs in animals. Although microRNAs occasionally do act in accordance with the classical view, we now know that each microRNA usually acts more as a rheostat to optimize the output of hundreds of messenger RNA targets, which can reinforce cell identity and sometimes sharpen developmental transitions."
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nOW Then
What I thought then… " When I started working on the kinetochore in graduate school, everyone assumed that it was a very simple structure, with just a handful of proteins involved in binding to the DNA and binding to the microtubule …"
What I know now… " …I think it was a huge surprise to people that the kinetochore is really made up of about 90 to 100 proteins. So instead of this very simple interface, it's this complex molecular machine. And that intricacy challenged the way people look at the molecular complexity of cell division's basic machinery."
Iain Cheeseman
Research in the Cheeseman lab revolves around the kinetochore, a protein complex essential to cell division.
The kinetochore has the large and difficult job of connecting two vastly different types of biological molecules:
DNA, which is made of nucleotides, and proteins, which are made of amino acids. The connection provided by the kinetochore must be able to withstand substantial physical force, especially during cell division, when it tows bulky chromosomes through highly viscous fluid filling the nucleus.
In preparation for cell division, the nucleus duplicates its What I thought then… " I used to think that once we had the genome sequenced, we would be able to make accurate predictions about phenotypes and gene expression. We thought a gene was turned on and off by the proteins that bound to the switches in front of the gene…"
What I know now… " …However, it's more complicated than I thought. Now we know that many proteins are controlled by non-coding RNAs. So now the question is, 'What is controlling the non-coding RNAs, and how do they work?' We don't know how they switch genes on and off."
What I thought then… " For years we've been able to work with mouse embryonic stem cells with two active X chromosomes, but we were never sure we could do this with human cells. Could we derive embryonic stem cells before they underwent X-chromosome inactivation? This had bothered us for a long time…"
What I know now… " …We took a big gamble four or five years ago to study the effects of oxygen levels, and none of this was eligible for federal funding. Thanks to generous private support, we pursued it. And I think now people will have to adopt this approach. We will also now want to see if X-chromosome inactivation is reversible."
Rudolf Jaenisch What I thought then… " I've been studying red cells since 1958. About 25 years ago, we were the first to isolate genes for key mammalian red cell proteins, including the first protein that facilitated glucose uptake. In the late 1980s, we cloned the Epo receptor and spent 20-odd years studying how Epo stimulates red cell production, and then 10 years ago, we began studying stem cells. What ties all of these projects together is their focus on the basic cell and molecular biology of genes and proteins important for human physiology and disease. "
What I know now… " …The underlying points for us over the long term have been the samethe synergism between a basic understanding of cell function and the questions that arise from an understanding of specific human diseases."
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What I thought then… " Although I thought that the machinery controlling cell metabolism would be conserved between divergent organisms, I assumed that in the regulation of cell division and development there would be more species-specific features than common regulators. Meiosis, in particular, was thought by researchers to be controlled uniquely in each eukaryote and even to have evolved multiple times independently!"
What I know now… " …The conservation of regulators from simple, single-cell eukaryotes to humans is remarkable. Two of the genes we discovered, because they are essential for DNA replication and meiotic chromosome segregation in Drosophila, play crucial roles in ensuring accurate human cell division. Paradoxically perhaps, while this conservation of crucial control genes is so striking, we are finding exceptional developmental situations in which regulatory proteins are used in distinct ways. These provide powerful models to uncover new functions for these proteins."
Terry Orr-Weaver What I thought then… " When I started studying the X and Y chromosomes in the early 1980s, everyone had accepted the standard textbook stories about them. The X was all about X-linked recessive disorders, like color blindness. We were all taught to recognize this pattern of inheritance. And the Y was seen as the partner for the X, with very few genes and a primary role in sex determination.
In 1990, when the SRY gene (the sex-determining gene on the Y chromosome) was discovered, a lot of folks jumped ship. I was wondering whether the Y had a future intellectually or whether it was time to move on. It looked like a pretty tenuous topic upon which to base a career."
What I know now… " …Today the Y looks better than ever, and taken together with the X, we see that what were once a pair of ordinary autosomes have, in a grand experiment of nature over hundreds of millions of years, become extraordinary. There's no hint of the richness of this grand experiment in biology textbooks. Where once it seemed this topic might be exhausted, I'm now convinced my career will be too short to explore its breadth and depth."
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What I thought then… " The advances in DNA sequencing would have been difficult to foresee even five years ago."
What I know now… " …All of a sudden, you can now sequence entire genomes or entire sets of RNA molecules. And that is clearly a tool we need to learn how to play with. We don't think we've seen the full range of possibilities of that methodology."
Hidde Ploegh
Research in Hidde Ploegh's lab, though varied, is united by a common approach: take advantage of naturally occurring processes to learn more about the immune system and infectious diseases. In doing so, the lab has managed to produce a number of elegant, highly effective tools for studying cell and organismal biology.
One of the latest of these tools is a mouse model that represents how the T cells of the immune system respond to infection. In a collaborating effort with the lab of Rudolf Jaenisch, the Ploegh lab used nuclear transfer to make mice from T cells. T cells can rearrange their genetic material to produce a specific receptor that can identify an antigen. In this work, the T cells were " I was used to creating mutants (in C. elegans) and then studying phenotypes emerging at the end of a developmental process to determine the function of genes. But it's not an approach that could really work well in planarians…"
What I know now… " …I really had to learn how to study gene function in an adult animal, which is quite different. Here, we start with a normal animal and pull the plug on individual genes to see what happens. It can be like dominoes falling, where one defect causes another, which causes another. It took a while to learn how to study gene function with this approach."
The development of RNA interference approaches and strategies for studying gene function is now enabling the lab to exploit the full potential of the planarian model.
Peter Reddien
Peter Reddien is captivated by regeneration-of tissues, organs, and even entire body parts. Reddien's lab is working toward uncovering some of the secrets behind the process by studying the planarian flatworm, an animal whose legendary regenerative powers enable it to re-grow a severed head, tail, or virtually any other part of its body.
Reddien has systematically examined the functions of more than 1,000 genes in planaria, cataloging the roles The lab is currently exploring the various factors that regulate neoblast activity.
31 nOW Then
What I thought then… " I came of age at a time when conducting loss-of-function (gene function) studies in mammalian systems was very, very hard to do and basically relied on genetically engineering mice…" " In studying signal transduction, the goal had been to find a single, straightforward pathway. We always drew arrows where 'A' talks to 'B', 'B' talks to 'C' and so on…"
What I know now… " …The advent of RNAi (RNA interference) completely changed how we tackle loss-of-function studies. This is a methodological approach that has dramatically increased the number of hypotheses we can test per unit time."
" …We never anticipated the complexity of these pathways and the multiple loops and levels of feedback. This knowledge is increasingly important in the cancer world. Perturbing a single system is quite a bit harder than we first thought."
David sabatini What I thought then… " I thought it would be relatively simple to understand many aspects of development…"
What I know now… " …but I'm constantly amazed now at how much of development seems to be about nuance. It's not just about which gene is necessary, but the amount of gene product involved, as well as timing of when that product is made. We have made enormous progress in describing many of the genes required, but the magnitude of the challenge to get the real picture of what's actually occurring, and the subtleties involved, is something I didn't appreciate 20 years ago."
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nOW Then
What I thought then… " I used to think that all the cancer cells in a tumor were identical…" " I used to think that metastasis was impossibly complex…"
What I know now… " …it's clear now that there are several kinds of cancer cells in a tumor, with cancer stem cells being the most important of them. This is a wrenching new reality requiring a recalibration of our thinking about how tumors grow and spread. Moreover, the fact that we could produce epithelial stem cells from normal epithelial cells also suggests a way to make epithelial stem cells that could not have been anticipated several years ago."
" …I now believe that we are within reach of some important concepts indicating that metastasis is much simpler and experimentally more accessible than we once thought it would be. This is a major conceptual shift. It's also far more satisfying to study metastasis with the realization that it's likely driven by a relatively small set of identifiable master regulators."
Robert Weinberg What I thought then… " There are about 2,000 genes that regulate gene control, and I used to think that in any one cell type, there were hundreds of these regulators, all working together in some really complex way…"
What I know now… " …It's become clear that in many cells, only a few key regulators can in fact program an entire cell state. The implication of that discovery is that a deep understanding of a few key regulators should lead us more rapidly to understand human development and how to control many diseases."
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Defne Yarar
The inside of a cell is a bustling place, with bubble-like vesicles zooming along protein cables, organelles churning out and modifying proteins, and mitochondria tearing molecules apart for energy. 
Andreas Hochwagen
Cell division is an intricate process. If anything goes awry, the resulting daughter cells can be plagued by genetic errors that can cause birth defects or cancer. Fortunately, our cells have built-in surveillance mechanisms, known as checkpoints, to prevent catastrophe. In the lab of Whitehead Fellow Andreas Hochwagen the role of these checkpoints during meiosis, the complex and error-prone cell division that gives rise to sperm and eggs, is under intense study. When cells undergo meiosis, they enter a stage of chromosome fragmentation and reshuffling that dramatically increases the risk for genetic mistakes. Scientists have long suspected that checkpoint surveillance is essential to ensuring that our genome emerges unscathed from this process. It had been thought, however, that checkpoints come into play only when chromosome repair fails. Now, research in the Hochwagen lab indicates that the checkpoint system is actually an integral part of normal meiosis. By studying the sexually reproducing baker's yeast, the Hochwagen lab has found that the checkpoint machinery acts much like a molecular master of ceremonies for meiosis. When breaks are detected, the checkpoint system coordinates break repair with chromosome movements and remodeling. The lab recently discovered the first molecular toggle that enables this coordination by triggering significant alterations in chromosome movement.
Whitehead Fellows
Thijn Brummelkamp
Thijn Brummelkamp focuses on cancer research and uses genetic screens to identify genes that play a role in human disease. His lab recently developed a novel screening approach that is having significant impact in the field of infectious disease. The basis of this new technique is a human cell line that is predominantly haploid-that is, each cell has only a single copy of each chromosome and, therefore, only a single copy of each gene. Using this cell line, the Brummelkamp lab is able to systematically, consistently, and reliably knock out the function of each non-essential gene and observe the result(s). Armed with these knockouts, the lab can pinpoint which genes and proteins these pathogens utilize when causing infection. In more than 20 independent screens, the lab has identified multiple host factors used by a variety of different bacterial toxins and viruses, including diphtheria toxin and influenza. And this is only the beginning. Having knockout cells for nearly all human genes "in the freezer," as Brummelkamp puts it, should enable the generation of a comprehensive overview of cellular factors directly implicated in infectious disease.
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Board and Philanthropy News 
Community Evolution
Never at rest, the Institute is constantly evolving and advancing in myriad ways. Some changes are subtle, others profound. In 2009, the Whitehead community saw its share of transitions. Simply put, stasis doesn't happen here. Owing to its financial strength, Whitehead Institute has been able to weather this period of global economic uncertainty and maintain its commitment to best-in-class science. The quality of Whitehead research allows the Institute's faculty and associated scientists to compete successfully for federal and non-federal funding, while the generosity of individuals, corporations, and foundations provides critical support where funding gaps might otherwise appear. Contributing to the Institute's fiscal stability, the administration continues to reduce operating expenses in a concerted effort to maximize research-specific spending. 
